BioSpace News Archive

Novel CryptigenTM technology unlocks full potential of Tumour Specific Antigens.

Medtronic plc announced that Laura Mauri, M.D., M.S.c. has been appointed Medtronic Chief Scientific, Medical and Regulatory Officer.

DBV Technologies announced that the Company will host a conference call and live audio webcast on Thursday, May 2, 2022, at 5:00 p.m. ET to report first quarter 2022 financial results and provide a corporate update.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending approval of KEYTRUDA.

FibroGen, Inc. will announce its first quarter 2022 financial results on Monday, May 9 after the market close.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, President and Chief Executive Officer of Tonix Pharmaceuticals, will present at B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference on Wednesday, April 27, 2022, at 1:00 p.m.ET.

OnKure, Inc. announced that the Company is expanding its operations with the opening of a research laboratory in Boulder, Colorado.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), today announced that the U.S. Food and Drug Administration (FDA) approved two new dosage strengths of CAPLYTA, 10.5 mg and 21 mg capsules, to provide dosage recommendations for patients concomitantly taking strong or moderate CYP3A4 inhibitors, and 21 mg for patients with moderate or severe hepatic impairment (Child-Pugh class B or C).

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive preliminary Phase 1 data from independent dose finding studies of its two lead chimeric antigen receptor (CAR) natural killer (NK) cell therapy candidates, NKX101 and NKX019, in two distinct groups of hematologic malignancies.

Autolus Therapeutics plc today announced that it will release its first quarter 2022 financial results and operational highlights before open of U.S. markets on Thursday, May 5, 2022.